Table 1.
Demographics, clinical characteristics, and CSF biomarker characteristics in DLB, AD, and controls
| DLB (n = 72) | AD (n = 38) | Controls (n = 38) | |
|---|---|---|---|
| Female (n, %) | 7 (10%) | 3 (8%) | 5 (13%) |
| Age (mean ± SD) | 68 ± 6 | 68 ± 6 | 67 ± 6 |
| MMSE (median [IQR]) | 23 [21–26]b | 22 [18–25]b | 29 [28–30] |
| APOEε4 carrier (n, %) | 39 (57%)a | 26 (72%)a | 12 (32%) |
| CSF AD biomarkers Innotest (median [IQR]) | |||
| Aβ1-42 (pg/ml)* | 790 [638–1040]b,d | 620 [562–660]b | 1123 [1022–1291] |
| t-tau (pg/ml) | 306 [228–368]b,d | 611 [498–791]b | 230 [187–271] |
| p-tau (pg/ml) | 47 [35–60]d | 79 [65–99]b | 44 [34–50] |
| CSF tau/Aβ42 > 0.52 (n, %) | 23 (33%)b,d | 38 (100%)b | 0 (0%) |
| CSF Aβ peptides MSD (mean ± SD) | |||
| Aβ42 (pg/ml) | 441 ± 185b,d | 304 ± 71b | 692 ± 205 |
| Aβ40 (pg/ml) | 5432 ± 1340a | 5897 ± 1066 | 6243 ± 1500 |
| Aβ38 (pg/ml) | 2247 ± 638a,c | 2524 ± 547 | 2676 ± 703 |
| Aβ42/Aβ40 ratio | 0.08 ± 0.03b,d | 0.05 ± 0.01b | 0.11 ± 0.02 |
| Aβ42/Aβ38 ratio | 0.20 ± 0.07b,d | 0.12 ± 0.03b | 0.26 ± 0.04 |
| Aβ38/Aβ40 ratio | 0.41 ± 0.03a,c | 0.43 ± 0.04 | 0.43 ± 0.02 |
Data are presented as mean ± SD, median [interquartile range], or n (%). Differences between groups were assessed with ANOVA, χ2, and Kruskal-Wallis H tests where appropriate. For CSFAβ peptides, differences between diagnostic groups were assessed using ANOVA corrected for multiple comparisons using a false discovery rate (FDR) correction
Abbreviations: Aβ42 amyloid β1-42 determined with MSD ELISA assay, Aβ40 amyloid β1-40 determined with MSD ELISA assay, Aβ38 amyloid β1-38 determined with MSD ELISA assay, AD Alzheimer’s disease, DLB dementia with Lewy bodies, MMSE mini-mental state examination, MSD Meso Scale Discovery
ap < 0.05 compared to controls; bp < 0.001 compared to controls; cp < 0.05 compared to AD; dp < 0.001 compared to AD
*Levels of Innotest Aβ1-42 were drift corrected [28]